Please use this identifier to cite or link to this item:
Title: Tenofovir as rescue therapy following clinical failure to lamivudine in severe acute hepatitis B
Authors: Gerada, Jurgen
Borg, Elaine
Formosa, Denise
Magro, Rosalie
Pocock, James
Keywords: Hepatitis B -- Diagnosis
Cell surface antigens
Clinical medicine -- Case studies
Issue Date: 2013
Publisher: Open Journal System
Citation: Gerada, J., Borg, E., Formosa, D., Magro, R., & Pocock, J. (2013). Tenofovir as rescue therapy following clinical failure to Lamivudine in severe acute hepatitis B. Mediterranean Journal of Hematology and Infectious Diseases, 5(1), 1-5.
Abstract: Acute hepatitis B (AHB) is a self-limiting condition in more than 95% of cases. Treatment is however recommended in patients with severe AHB (<1% of cases), aiming to prevent liver failure and death. Various nucleos(t)ide analogues (NA) have been found to be effective in severe AHB, although NA-resistant strains causing AHB have been also recently reported. The use of tenofovir in severe AHB has only been described in 3 cases (1 adult and 1 infant with HBV mono-infection, 1 adult with HBV/HIV co-infection). We hereby report a 47-year-old treatment-naïve male, who developed severe AHB and was initially treated with lamivudine (LMV). Initial rapid biochemical response was followed by biochemical breakthrough after 9 days, suggesting LMV resistance. Rescue therapy with ‘add-on’ tenofovir brought about a sustained improvement in biochemical, serological and virological markers until HBsAg was lost after 4 months. Thus, this is the second adult HBV mono-infected patient, who responded successfully to tenofovir in severe AHB.
Appears in Collections:Scholarly Works - FacM&SMed

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.